Literature DB >> 28664475

Discordance Rate of HER2 Status in Primary Gastric Cancer and Synchronous Lymph Node Metastases: Its Impact on Therapeutic Decision and Clinical Management.

A Ieni1, G Angelico2, G Giuffrè3, G Tuccari3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28664475     DOI： 10.1007/s12253-017-0276-5

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN： 1219-4956            Impact factor:   3.201


× No keyword cloud information.
  10 in total

1.  Extra-gain of HER2-positive cases through HER2 reassessment in primary and metastatic sites in advanced gastric cancer with initially HER2-negative primary tumours: Results of GASTric cancer HER2 reassessment study 1 (GASTHER1).

Authors:  Sook Ryun Park; Young Soo Park; Min-Hee Ryu; Baek-Yeol Ryoo; Chang Gok Woo; Hwoon-Yong Jung; Jeong Hoon Lee; Gin Hyug Lee; Yoon-Koo Kang
Journal:  Eur J Cancer       Date:  2015-12-13       Impact factor: 9.162

2.  HER2 status of gastric carcinoma and corresponding lymph node metastasis.

Authors:  Fabio Pagni; Stefano Zannella; Susanna Ronchi; Cristina Garanzini; Biagio Eugenio Leone
Journal:  Pathol Oncol Res       Date:  2012-08-21       Impact factor: 3.201

Review 3.  HER2 heterogeneity in gastric/gastroesophageal cancers: From benchside to practice.

Authors:  Federica Grillo; Matteo Fassan; Francesca Sarocchi; Roberto Fiocca; Luca Mastracci
Journal:  World J Gastroenterol       Date:  2016-07-14       Impact factor: 5.742

4.  HER2 Status in Gastric Cancer: Comparison between Primary and Distant Metastatic Disease.

Authors:  Michelina Amato; Giuseppe Perrone; Daniela Righi; Claudio Pellegrini; Carla Rabitti; Francesco Di Matteo; Pierfilippo Crucitti; Damiano Caputo; Roberto Coppola; Giuseppe Tonini; Daniele Santini; Andrea Onetti Muda
Journal:  Pathol Oncol Res       Date:  2016-06-30       Impact factor: 3.201

5.  Minimum biopsy set for HER2 evaluation in gastric and gastro-esophageal junction cancer.

Authors:  Irene Gullo; Federica Grillo; Luca Molinaro; Matteo Fassan; Annalisa De Silvestri; Carmine Tinelli; Massimo Rugge; Roberto Fiocca; Luca Mastracci
Journal:  Endosc Int Open       Date:  2015-02-03

6.  Discordance rate of HER2 status in primary gastric carcinomas and synchronous lymph node metastases: a multicenter retrospective analysis.

Authors:  Antonio Ieni; Valeria Barresi; Rosario Caltabiano; Alessia Caleo; Luca Reggiani Bonetti; Salvatore Lanzafame; Pio Zeppa; Rosario Alberto Caruso; Giovanni Tuccari
Journal:  Int J Mol Sci       Date:  2014-12-03       Impact factor: 5.923

7.  Ideal number of biopsy tumor fragments for predicting HER2 status in gastric carcinoma resection specimens.

Authors:  Sangjeong Ahn; Soomin Ahn; Michael Van Vrancken; Minju Lee; Sang Yun Ha; Hyuk Lee; Byung-Hoon Min; Jun Haeng Lee; Jae J Kim; Sunkyu Choi; Sin-Ho Jung; Min Gew Choi; Jun-Ho Lee; Tae Sung Sohn; Jae Moon Bae; Sung Kim; Kyoung-Mee Kim
Journal:  Oncotarget       Date:  2015-11-10

8.  Differing deregulation of HER2 in primary gastric cancer and synchronous related metastatic lymph nodes.

Authors:  Mitsugu Kochi; Masashi Fujii; Shinobu Masuda; Noriaki Kanamori; Yoshiaki Mihara; Tomoya Funada; Hidenori Tamegai; Megumu Watanabe; Hiroshi Suda; Tadatoshi Takayama
Journal:  Diagn Pathol       Date:  2013-11-21       Impact factor: 2.644

9.  Discordance rate of HER2 status in primary breast carcinomas versus synchronous axillary lymph node metastases: a multicenter retrospective investigation.

Authors:  Antonio Ieni; Valeria Barresi; Rosario Caltabiano; Anna Maria Cascone; Rachele Del Sordo; Daniela Cabibi; Pio Zeppa; Salvatore Lanzafame; Angelo Sidoni; Vito Franco; Giovanni Tuccari
Journal:  Onco Targets Ther       Date:  2014-07-11       Impact factor: 4.147

Review 10.  HER2 Status in Premalignant, Early, and Advanced Neoplastic Lesions of the Stomach.

Authors:  A Ieni; V Barresi; L Rigoli; R A Caruso; G Tuccari
Journal:  Dis Markers       Date:  2015-10-01       Impact factor: 3.434
  10 in total
  1 in total

1.  Local and Central Evaluation of HER2 Positivity and Clinical Outcome in Advanced Gastric and Gastroesophageal Cancer-Results from the AGMT GASTRIC-5 Registry.

Authors:  Florian Huemer; Lukas Weiss; Peter Regitnig; Thomas Winder; Bernd Hartmann; Josef Thaler; Gudrun Piringer; Clemens A Schmitt; Wolfgang Eisterer; Hannes Gänzer; Alois Wüstner; Johannes Andel; Björn Jagdt; Hanno Ulmer; Richard Greil; Ewald Wöll
Journal:  J Clin Med       Date:  2020-03-29       Impact factor: 4.241
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.